The OX40 ligand inhibitors market is emerging as a promising segment within the immuno-oncology landscape, with growing attention from researchers, biotech firms, and pharmaceutical companies. OX40 (also known as CD134) is a co-stimulatory molecule found on T cells, and its interaction with the OX40 ligand (OX40L) plays a pivotal role in regulating immune responses, especially in the...